Navigation Links
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
Date:9/24/2007

S. prevalence is nearly 30,000 and the incidence is 1.2 per 100,000. Only a single drug has been approved for the treatment of ALS. Life expectancy after symptom onset is usually three to five years.

About Knopp Neurosciences Inc. (http://www.knoppneurosciences.com)

Knopp Neurosciences is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company's lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp's leadership includes experienced neuroscience drug development and discovery executives formerly associated with major pharmaceutical companies. Knopp's financing has been led Saturn Capital Inc. of Boston as placement agent and Saturn Partners II as lead funder.

This press release contains "forward-looking statements," including statements relating to Knopp's planned regulatory filings and clinical development programs for KNS-760704. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that KNS-760704 will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the products. Knopp undertakes no obligation to update or revise any such forward-looking statement
'/>"/>

SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... VANCOUVER, British Columbia , March 5, 2015 ... BMKDF) -- The ultimate goal in the cancer diagnostics ... of detecting tumors before they become disruptive, metastatic and ... such an assay has been the holy grail ... many breakthrough diagnostics have been invented such as ELISA-based ...
(Date:3/4/2015)... , March 4, 2015  Hill-Rom Holdings, Inc. (NYSE: ... Enxing Seng has been elected to its Board ... in Residence for Covidien, as well as President of ... of Peripheral Vascular from 2010 to 2012. ... $2.6B acquisition of ev3 Incorporated, where she was a ...
(Date:3/4/2015)... China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or ... in China, today announced its financial results for the ... Fourth Quarter 2014 Financial Highlights , Total ... 36.2%, or 36.8% excluding the impact of foreign currency ... in the same quarter of 2013. , Gross ...
Breaking Medicine Technology:New Cancer Diagnostic Primed to Change the Industry 2New Cancer Diagnostic Primed to Change the Industry 3New Cancer Diagnostic Primed to Change the Industry 4Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22
(Date:3/5/2015)... (PRWEB) March 05, 2015 Leading nutritional ... this week’s Arnold Sports Festival and Arnold Fitness ... Metabolic Nutrition will host a display booth featuring ... pre-workout E.S.P. and its highly-popular, class-leading fat burner Synedrex. ... cups, unique recipes that utilize its top-of-the-line supplements and ...
(Date:3/5/2015)... Think it’s tough to get kids to ... them to brush their teeth. That’s a finding from a ... Delta Dental(1) in conjunction with National Parenting Month in March. ... kids to brush their teeth is one of the most ... higher than getting children to eat vegetables regularly (42 percent) ...
(Date:3/5/2015)... The recent influx of online ... alarming, with more and more internet ads offering “prescription” ... making it easy for more people to fall prey ... and endanger their health. The company urges consumers to ... diet pills: , 1.    Where are the products manufactured and ...
(Date:3/5/2015)... MTC 5-day Fundamental Implantology Course has been developed by ... dental disciplines, to offer implant placement treatment to their ... wanted this course to be a truly empowering experience ... the lecturers and the sheer energy and enthusiasm of ... aims." , Unlike large-scale training operations, the MTC ...
(Date:3/5/2015)... Hope For The Warriors® is excited to ... be held at Beretta Shooting Grounds (Dover Furnace) in Dover ... the event will benefit Hope For The Warriors®, a national ... family unit, and restoring hope for our service members and ... heroes through a day of clay shooting at Beretta Shooting ...
Breaking Medicine News(10 mins):Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 3Health News:MIS Global Training Center (MTC) Launches its Fundamental Implantology Course for Doctors - with a Difference 2Health News:Hope For The Warriors Announces New York Clay Shoot to Benefit Military Families 2
... 1970s, U.S. mortality rates due to colorectal cancer have ... rates rose. Evidence suggests that underuse of colonoscopy screening ... disparities. In 2003, New York City launched a multifaceted ... minorities and women. A new study conducted by researchers ...
... News) -- Women who develop breast tenderness after starting combination ... risk of developing breast cancer than those who don,t experience ... that new-onset breast tenderness was not associated with increased breast ... based on an analysis of data from more than 16,600 ...
... WINSTON-SALEM, N.C. -- Researchers at Wake Forest Baptist Medical ... are teaming up for a research project aimed at ... stress disorder (PTSD) and traumatic brain injury (TBI). ... our vets coming home from Iraq and Afghanistan," said ...
... HealthDay Reporter , FRIDAY, Nov. 18 (HealthDay News) -- ... didn,t stem from any aversion to them. "I love salad ... a Baltimore resident who said her love of vegetables stemmed from ... brought up that way -- so we always ate vegetables." ...
... , LA JOLLA, CA November 17, 2011 - A ... the Novartis Research Foundation (GNF) and The Scripps Research Institute ... to a new generation of antimalarial drugs capable of not ... In a study published November 17, 2011, in Science Express, ...
... , THURSDAY, Nov. 17 (HealthDay News) -- ... person,s cholesterol, including weakening the function of high-density lipoprotein ... researchers said that, if confirmed, their findings could help ... condition -- are at greater risk for heart attack, ...
Cached Medicine News:Health News:Colon cancer screening campaign erases racial, gender gaps in use of colonoscopy 2Health News:Colon cancer screening campaign erases racial, gender gaps in use of colonoscopy 3Health News:Tender Breasts From Combo HRT Linked to Higher Cancer Risk 2Health News:Hope on the horizon for patients with post-traumatic stress disorder 2Health News:Hope on the horizon for patients with post-traumatic stress disorder 3Health News:Not Everyone Shuns Fruits and Veggies 2Health News:Scripps Research scientists identify new class of antimalarial compounds 2Health News:Scripps Research scientists identify new class of antimalarial compounds 3Health News:Scripps Research scientists identify new class of antimalarial compounds 4Health News:Does Psoriasis Thwart the Benefits of 'Good' Cholesterol? 2
Bone Curette, 180 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Townsend is a endocervical stainless-steel curette with round tapered tip....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Medicine Products: